Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

@article{Marty2011MaribavirPF,
  title={Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.},
  author={Francisco M Marty and Per Ljungman and Genovefa Anna Papanicolaou and Drew J. Winston and Roy F Chemaly and Lynne M Strasfeld and Jo-Anne H Young and Tulio E. Rodriguez and Johan Maertens and Michael Schmitt and Hermann Einsele and Augustin Ferrant and Jeffrey Howard Lipton and Stephen A Villano and Hongzi Chen and Michael Boeckh},
  journal={The Lancet. Infectious diseases},
  year={2011},
  volume={11 4},
  pages={284-92}
}
BACKGROUND Available drugs against cytomegalovirus have adverse effects that compromise their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients. METHODS In this placebo-controlled, randomised, double-blind, multicentre phase 3 study, we enrolled adult patients recipient-seropositive or donor-seropositive for cytomegalovirus who had undergone allogeneic stem-cell transplantation… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
82 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

Similar Papers

Loading similar papers…